Schott expects orforglipron's side effect profile to land "worse than Zepbound but closer to Wegovy" for obesity patients
A licensed provider reviews your profile to determine if a GLP-1 medication or a combination therapy is safe and appropriate for you

Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions

For both BrAC and subjective feelings of drunkenness, area under the curve (AUC) was calculated using the trapezoidal rule (with x as time in minutes and y as the outcome)
Some of the reactions included, "Serena Williams can be doing so much to champion womens sports or the importance of body positivity, but instead is pushing a weight loss drug in her retirement." "This is so f***ing ridiculous and backwards serena williams is a retired tennis legend her body has won her so many awards and titles why the f**k is she promoting glp-1," and "Why is a world class athlete like Serena Williams promoting GLP-1s
Overall, the combination therapy showed significant reductions in the primary composite outcome (all-cause hospitalization, all-cause mortality, MACE, MAKE, and MALO) by 13%